

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date:	April 1, 2013
Original Effective Date:	
Revision Date:	November 23, 2015, September 7, 2017, January 24, 2024, March 18, 2025,
	April 4, 2025

Zyprexa Relprevv® (olanzapine)

LENGTH OF AUTHORIZATION: Maximum of six months

THIS MEDICATION MAY RECEIVE APPROVAL UNDER TWO CRITERIA

REVIEW CRITERIA:

- Must have diagnosis of schizophrenia; AND
- Patient must be \geq 18 years old; **AND**
- Must be prescribed by a provider that has enrolled in the Zyprexa Relprevv® Patient Care Program demonstrated with supporting documentation (signed attestation):
 http://multivu.prnewswire.com/mnr/lilly/40089/docs/40089-
 ZyprexaRelprevvPatientCareProgramBackgrounder121409CLEAN(2).pdf
- <u>Trial and failure of Risperdal Consta® or a recommendation from the first two bulleted statements below if applicable:</u>
 - Hypersensitivity (allergy) or adverse response to oral olanzapine therapy is not a reason for approval. The provider should try other preferred oral antipsychotic agents or preferred long-acting injectables.
 - Ineffectiveness of oral olanzapine therapy is not a reason for approval. The provider should try
 other oral atypical antipsychotic agents. The provider should try other preferred oral
 antipsychotic agents or preferred long-acting injectables.
 - o <u>Failure</u> of Risperdal Consta[®] is defined as an occurrence of intolerable adverse effect(s) (for example: constipation, extrapyrimadal symptoms (EPS), or cardiac events).
 - <u>Failure</u> may also be defined as "ineffectiveness of Risperdal Consta® therapy" if the patient has received a minimum of a one-month trial on the optimal dose of 50 mg every 2 weeks. (This must be verified in claims history or progress notes).

ALTERNATE REVIEW CRITERIA

- Clinical documentation of medical necessity because:
 - The patient has a diagnosis of schizophrenia, schizotypal or delusional disorder and meets the following:
 - The drug product or medication of a similar drug class is prescribed for the treatment of schizophrenia or schizotypal or delusional disorders; -AND-
 - Prior authorization has been granted previously for the prescribed drug; -AND-
 - The medication was dispensed to the patient during the previous 12 months



Zyprexa Relprevv® is available only through a restricted distribution program. Zyprexa Relprevv® must not be dispensed directly to a patient. For a patient to receive treatment, the prescriber, healthcare facility, patient, and pharmacy must all be enrolled in the Zyprexa Relprevv® Patient Care Program (phone # 1-877-772-9390).





Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date:	April 1, 2013
Original Effective Date:	
Revision Date:	November 23, 2015, September 7, 2017, January 24, 2024, March 18, 2025,
	April 4, 2025

CONTINUATION following ACUTE THERAPY:


- If the beneficiary has previously received Zyprexa Relprevv® as acute treatment (e.g. during institutionalization or hospitalization) and the provider is requesting continuation of therapy upon discharge:
 - o If there is <u>no</u> trial history of Risperdal Consta[®] the request must be denied.
 - o If there is trial of Risperdal Consta[®] (either in documentation or claims history) within the past 365 days refer to #3 of the review criteria.

CONTINUATION following CHRONIC THERAPY:

• The beneficiary must have documentation (e.g. paid prescription claims and documented administration history) of uninterrupted (100% compliance) Zyprexa Relprevv® therapy during the past 90 days and documented effectiveness.

DOSING AND ADMINISTRATION:

- Available as powder for suspension for single-dose intramuscular use only: 210 mg/vial, 300 mg/vial, and 405 mg/vial.
- Refer to product labeling at https://www.accessdata.fda.gov/scripts/cder/daf/





Zyprexa Relprevv® is available only through a restricted distribution program. Zyprexa Relprevv® must not be